Cargando…

Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma

Cytogenetic evaluation at the time of diagnosis is essential for risk stratification in multiple myeloma, however little is known about the occurrence and prognostic significance of cytogenetic evolution during follow-up. We studied 989 patients with multiple myeloma, including 304 patients with at...

Descripción completa

Detalles Bibliográficos
Autores principales:	Binder, M, Rajkumar, S V, Ketterling, R P, Dispenzieri, A, Lacy, M Q, Gertz, M A, Buadi, F K, Hayman, S R, Hwa, Y L, Zeldenrust, S R, Lust, J A, Russell, S J, Leung, N, Kapoor, P, Go, R S, Gonsalves, W I, Kyle, R A, Kumar, S K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4817098/ https://www.ncbi.nlm.nih.gov/pubmed/26967818 http://dx.doi.org/10.1038/bcj.2016.15

Ejemplares similares

Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma
por: Binder, M, et al.
Publicado: (2017)

Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma
por: Gonsalves, W I, et al.
Publicado: (2015)

Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response
por: Abdallah, Nadine, et al.
Publicado: (2020)

Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death
por: Warsame, R, et al.
Publicado: (2015)

Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma
por: Tandon, N, et al.
Publicado: (2017)

Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma
por: Ravi, P, et al.
Publicado: (2017)

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
por: Kumar, Shaji K., et al.
Publicado: (2013)

N‐terminal fragment of the type‐B natriuretic peptide (NT‐proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma
por: Milani, Paolo, et al.
Publicado: (2016)

Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma
por: Ravi, P, et al.
Publicado: (2016)

Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma
por: Vu, T, et al.
Publicado: (2015)

Natural history of multiple myeloma with de novo del(17p)
por: Lakshman, Arjun, et al.
Publicado: (2019)

P-208: Association of thrombocytopenia with disease burden, high-risk cytogenetics, and survival in newly diagnosed multiple myeloma patients
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Beta‐blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation
por: Hwa, Yi L., et al.
Publicado: (2016)

Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria
por: Lakshman, Arjun, et al.
Publicado: (2018)

Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome
por: Paquin, Ashley R., et al.
Publicado: (2018)

Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy
por: Siontis, B, et al.
Publicado: (2015)

Utility of Serum Free Light Chain Measurements in Multiple Myeloma Patients Not Achieving Complete Response to Therapy
por: Moustafa, Muhamad Alhaj, et al.
Publicado: (2015)

Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era
por: Chakraborty, R, et al.
Publicado: (2016)

P884: POTENTIAL BENEFIT OF POST-TRANSPLANT DOXYCYCLINE IN AL ACHIEVING HEMATOLOGICAL RESPONSE AFTER AUTOLOGOUS STEM CELL TRANSPLANT – LONG TERM FOLLOW UP
por: Abdallah, N., et al.
Publicado: (2022)

“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience
por: Vaxman, I., et al.
Publicado: (2021)

Second- and third-line treatment strategies in multiple myeloma: a referral-center experience
por: Goldman-Mazur, Sarah, et al.
Publicado: (2022)

Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma
por: Ravi, Praful, et al.
Publicado: (2018)

Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis
por: Visram, Alissa, et al.
Publicado: (2021)

Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma
por: Paquin, Ashley, et al.
Publicado: (2020)

Outcomes after biochemical or clinical progression in patients with multiple myeloma
por: Goldman-Mazur, Sarah, et al.
Publicado: (2022)

Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma
por: Tschautscher, Marcella A., et al.
Publicado: (2020)

Long-term outcomes of allogeneic stem cell transplant in multiple myeloma
por: Schmidt, Walker M., et al.
Publicado: (2023)

The Impact of Re-induction Prior to Salvage Autologous Stem Cell Transplantation in Multiple Myeloma
por: Miller, Kevin C., et al.
Publicado: (2019)

Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients
por: Visram, Alissa, et al.
Publicado: (2021)

Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma
por: Goel, Utkarsh, et al.
Publicado: (2023)

Acute Acquired Fanconi Syndrome in Multiple Myeloma After Hematopoietic Stem Cell Transplantation
por: Sy-Go, Janina Paula T., et al.
Publicado: (2020)

Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy
por: Charalampous, Charalampos, et al.
Publicado: (2023)

Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma
por: Kumar, Shaji K., et al.
Publicado: (2018)

Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience
por: Vaxman, I., et al.
Publicado: (2023)

Comparable Outcomes using Propylene Glycol-Free Melphalan for Autologous Stem Cell Transplantation in Multiple Myeloma
por: Miller, Kevin C., et al.
Publicado: (2018)

A simple additive staging system for newly diagnosed multiple myeloma
por: Abdallah, Nadine H., et al.
Publicado: (2022)

Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Mode of Progression in Smoldering Multiple Myeloma: A study of 406 patients
por: Rajkumar, S, et al.
Publicado: (2023)

Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design
por: Vaxman, I., et al.
Publicado: (2021)

Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation
por: Roy, V, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_daacnh6nf13jkhiek11447mkr1